European Medicines Agency
© emea 2006 2 impurities testing guideline: impurities in new drug substances table of contents 1. preamble 3 2. classification of impurities 3
Download European Medicines Agency
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Q 3 B (R2) Impurities in New Drug Products
www.ema.europa.eu© EMEA 2006 3 IMPURITIES IN NEW DRUG PRODUCTS I. INTRODUCTION 1.1 Objective of the guideline This document provides guidance for registration applications on the content and qualification
Regulatory Considerations for Peptide Drug Products
www.gphaonline.orgRegulatory Considerations for Peptide Drug Products Larisa C. Wu Peptide Team OGD/CDER/FDA 2013 GPhA/FDA CMC Workshop June 5, 2013 This presentation reflects the views of the author and
1 Purity Analysis and Impurities Determination by …
www.is3na.org1 1Purity Analysis and Impurities Determination by Reversed-Phase High-Performance Liquid Chromatography Hagen Cramer, Kevin J. Finn, and Eric Herzberg Girindus America, Inc.
ICH Topic Q 1 A Stability Testing Guidelines: …
www.pharma.gally.chCPMP/ICH/380/95 1/13 STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS ICH Harmonised Tripartite Guideline [EMEA Status as …
IMPURITIES IN EW DRUG SUBSTANCES Q3A(R2) - …
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised tripartite guideline impurities in new drug substances
USP ELEMENTAL IMPURITIES TO REPLACE USP …
www.sgs.comauthor: gayla velez, director, analytical services, sgs life science services, usa usp elemental impurities to replace usp <231> heavy metals
Related search queries
IMPURITIES IN NEW DRUG PRODUCTS, Regulatory Considerations for Peptide Drug Products, Purity Analysis and Impurities Determination by, Analysis and Impurities Determination by, A Stability Testing Guidelines:, NEW DRUG, PRODUCTS, IMPURITIES IN, DRUG SUBSTANCES, Impurities in new drug substances, Impurities